NCT05291845

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 162 (estimated)
• Sponsor: Zagazig University · Other Government
• Sex: All
• Age: 9 Years
• Healthy volunteers: Not accepted

Summary

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

Detailed description

* Group A: 54 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions. * Group B: 54 patients will be treated with bivalent HPV vaccine solution intralesional into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions. * Group C: 54 patients will be treated with both agents intralesionally into the largest wart using an insulin syringe at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions. it is thought that candida antigen act through a cell-mediated immune response and bivalent HPV vaccine act mainly through humoral immunity, so we want to study their effect as single or mixed agents

Conditions

• Warts
• Human Papilloma Virus

Interventions

Type	Name	Description
BIOLOGICAL	Candida antigen vaccine	we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
BIOLOGICAL	Bivalent HPV vaccine	we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group

Timeline

• Start date: 2022-04-03
• Primary completion: 2025-10-03
• Completion: 2025-12-06
• First posted: 2022-03-23
• Last updated: 2025-06-12

Locations

1 site across 1 country: Egypt